Drug profile · INN
acrivastine
SEMPREX-D
acrivastine (SEMPREX-D) is a histamine h1 receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — acrivastine
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
acrivastine (SEMPREX-D) is a histamine h1 receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Histamine H1 receptor antagonist
Primary target: Histamine H1 receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is acrivastine?
acrivastine (SEMPREX-D) is a histamine h1 receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for acrivastine?
SEMPREX-D is a marketed brand name for acrivastine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of acrivastine?
acrivastine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.